Cetuximab Antibody ELISA Kit

Catalog No. ABIN2862667

Product Details

Target: Cetuximab Antibody

Binding Specificity: Free Chain

Reactivity: Chemical, Human

Detection Method: Colorimetric

Method Type: Sandwich ELISA

Application: ELISA

Purpose: Enzyme immunoassay for the semi-quantitative determination of free antibodies to Cetuximab in human serum and plasma samples.

Brand: ImmunoGuide®

Sample Type: Serum, Plasma (EDTA - heparin)

Analytical Method: Semi-Quantitative

Specificity: Free antibodies against Cetuximab (Erbitux®)S creening test was performed with 90 different native and RF-negative human sera. 88 samples produced OD values between 0.047 and 0.069, which is less than the cut-off value (3x 0.060). One of the higher samples showed an OD of 0.105 and the other one of 0.089.

Sensitivity: 10 ng/mL

Characteristics: This test does not measure the antibodies if they already are bound to the drug Cetuximab

Components:

• 1 x 12 x 8 Microtiter Plate Break apart strips pre-coated with the drug Cetuximab.
• 1 x 2 mL Positive Control Ready to use. Contains reactive antibody, proteins, stabilizer and <15mM NaN3.
• 1 x 2 mL Negative Control Ready to use. Contains human serum, stabilizer and <15mM NaN3.
• 1 x 60 mL Assay Buffer Blue colored. Ready to use. Contains proteins and <15mM NaN3.
• 1 x 12 mL Enzyme Conjugate Red colored. Ready to use. Contains horseradish peroxidase(HRP)-conjugated Cetuximab, Proclin® and stabilizers.
• 1 x 12 mL TMB Substrate Solution Ready to use. Contains 3,3',5,5'-Tetramethylbenzidine (TMB).
• 1 x 12 mL Stop Solution Ready to use. 1 N Hydrochloric acid (HCl).
• 1 x 50 mL Wash Buffer, Concentrate (20x) Contains buffer, Tween® 20 and KathonTM.
• 2 x 1 Adhesive Seal For sealing microtiter plate during incubation.

Material not included:

• Micropipettes (< 3 % CV) and tips to deliver 5-1000 μL.
• Bidistilled or deionised water and calibrated glasswares (e.g. flasks or cylinders).
• Wash bottle, automated or semi-automated microtiter plate washing system.
• Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength at 600-650 nm is optional).
• Absorbent paper towels, standard laboratory glass or plastic vials, and a timer.

Application Details

Application Notes:

• Before performing the assay, samples and assay kit should be brought to room temperature (about 30 minutes beforehand) and ensure the homogeneity of the solution.
• All Standards should be run with each series of unknown samples.
• Standards should be subject to the same manipulations and incubation times as the samples being tested.
• All steps of the test should be completed without interruption.
• Use new disposable plastic pipette tips for each reagent, standard or specimen in order to avoid cross contamination.

Comment:

Antibody to Cetuximab ELISA is also suitable for using by an automated ELISA processor.

Sample Volume: 5 μL

Assay Time: 2.5 h

Plate: Pre-coated

Protocol: The Antibody to Cetuximab ELISA is a sandwich type ELISA for the determination of free antibodies against Cetuximab in serum and plasma samples. During the first incubation period, antibodies to Cetuximab in patient serum/plasma samples are captured by the drug Cetuximab coated on the wall of the microtiter wells. After washing away the unbound components from samples, a peroxidase-labelled Cetuximab conjugate is added and then incubated. Antibody to Cetuximab, if present in sample, will make a bridge, with its two identical Fab arms, between the Cetuximab coated on the well and the other Cetuximab labeled with peroxidase. After a second washing step, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen-substrate. Finally, the reaction is terminated with stop solution. The positive reaction is related to the presence of antibodies to Cetuximab in the sample.

Reagent Preparation:

Wash Buffer: Dilute 10 mL Wash Buffer (up to 200 mL) at the ratio of 1:20 with distilled water.
Warm up at 37 °C to dissolve crystals. Mix vigorously.
Store at 2-8 °C for up to 4 weeks.
Prepare Wash Buffer before starting the assay procedure.

Sample Collection: Normal serum or plasma collection

Sample Preparation:

Serum/ Plasma: Dilute Serum/ Plasma (Sample) at the ratio of 1:101 with Assay Buffer.
For dilution at 1:101, 5 μL Sample + 500 μL Assay Buffer
Negative and Positive Controls are ready-to-use and should NOT be diluted with the assay buffer.

Serum, Plasma (EDTA, Heparin): The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Storage: 2-8 °C &leq,-20 °C (Aliquots)
Keep away from heat or direct sun light.
Avoid repeated freeze-thaw cycles.
Stability: 3 days at 2-8 °C, 6 months at -20 °C

Assay Procedure:

1. Pipette 100 μL of each Ready-to Use Negative Control, Positive Control, and 1:101 Diluted Samples (as described in section 10.2) into the respective wells of microtiter plate. Wells A1: Negative Control B1: Negative Control C1: Positive Control D1 and so on: Diluted samples (Serum/Plasma)
2. Cover the plate with adhesive seal. Shake plate carefully. Incubate 60 min at room temperature (RT) (18-25 °C).
3. Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 3 X 300 μL of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel.
4. Pipette 100 μL of Enzyme Conjugate (HRP-Cetuximab) into each well.
5. Cover plate with adhesive seal. Shake plate carefully. Incubate 60 min at RT.
6. Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 3 X 300 μL of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel.
7. Pipette 100 μL of Ready-to-Use TMB Substrate Solution into each well.
8. Incubate 20 min at RT. Avoid exposure to direct sunlight..
9. Stop the substrate reaction by adding 100 μL of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow.
10. Measure optical density (OD) with a photometer at 450 nm (Reference at OD620nm is optional) within 15 min after pipetting the Stop Solution.

Calculation of Results:

For the run to be valid, the OD450 nm of the Positive Control should be ≥ 1.000 and the OD450 nm of each Negative Control should be ≤0.150. If not, improper technique or reagent deterioration may be suspected and the run should be repeated. The results are evaluated by dividing all individual results by the mean OD450nm of the Negative Controls. The results are expressed in arbitrary units (AU/mL).

Range: > 3 AU/mL (Positive)
Range: &leq, 3 AU/mL (Negative)

The results themselves should not be the only reason for any therapeutical consequences. They have to be correlated to other clinical observations.

Sample calculation for a positive sample:
OD of sample = 0.740 Cut-off = 3 x
Average OD of Negative Controls = 3 x 0.100 = 0.300 = 3 AU/mL
Concentration of sample = 0.740/0.100 = 7.4 AU/mL (positive)

Assay Precision: Intra-assay CV: <10%.
Inter-assay CV: <10%

Restrictions: For Research Use only

Handling

Buffer: < 15mM NaN3

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The kit is shipped at ambient temperature and should be stored at 2-8°C.
Keep away from heat or direct sun light.
The storage and stability of specimen and prepared reagents is stated in the corresponding chapters.
The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.

Expiry Date: 24 months

Target Details

Target: Cetuximab Antibody

Target Type: Antibody

Background: Cetuximab is a human-mouse chimeric immunoglobulin (Ig) G1κ, monoclonal antibody (mAb), selectively directed against the epidermal growth factor receptor (EGFR), also known as HER1 or ErbB1. Since its approval by Food and Drug Administration for cancer treatment in 2004, Cetuximab became widely used in the treatment of colorectal and head and neck cancers. Phase I and II studies reported cetuximab trough and peak concentrations of 0- 108 mg/L and 130-298 mg/L, respectively. Initial studies reported relationships both between cetuximab cutaneous toxicity and therapeutic effect and between cetuximab concentrations and cutaneous toxicity. These data provide indirect evidence for the potential interest of therapeutic drug monitoring of Cetuximab, based on the measurement of its serum concentrations in treated patients. Recently it also reported that there is a correlation between cetuximab trough levels and antitumor response on Cetuximab monotherapy. According to the prescribing information, antibodies to Cetuximab could be detected in nearly 5 % of patients treated with Cetuximab. The Antibody to Cetuximab ELISA Kit can be efficiently used for monitoring Anti- Cetuximab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures to reduce Anti-Cetuximab antibodies.

Molecular Weight: 144 kDa